

Web Table 1. Baseline^a Characteristics for Participants (N=85,850) in the Women’s Health Initiative Dietary Modification Trial Comparison Group and Observational Study, Enrolled During 1994-1998, by Quartile of the Calibrated Ratio of Sodium to Potassium Intake

		Quartile of the Calibrated Ratio of Sodium to Potassium Intake							
		1 st		2 nd		3 rd		4 th	
		(N=21463)		(N=21462)		(N=21462)		(N=21463)	
		%	N ^b	%	N ^b	%	N ^b	%	N ^b
Age (years)	50-59	28.1	6,035	31.3	6,719	32.1	6,888	38.5	8,263
	60-69	44.3	9,514	45.5	9,762	46.1	9,887	45.8	9,838
	70-79	27.4	5,881	23.1	4,957	21.7	4,656	15.6	3,338
	80-85	0.2	33	0.1	24	0.1	31	0.1	23
BMI (kg/m ²)	Normal (< 25.0)	61.9	13,278	44.7	9,602	30.6	6,575	14.6	3,141
	Overweight (25.0 - 29.9)	30.3	6,502	38.1	8,168	39.4	8,460	31.0	6,658
	Obese (≥ 30)	7.8	1,683	17.2	3,692	29.9	6,427	54.3	11,664
Recreational physical activity (MET – hours/week)	< 1.5	10.0	2,149	14.0	3,000	20.2	4,328	29.9	6,422
	1.5 - 6.2	16.2	3,468	20.3	4,352	22.7	4,880	25.8	5,542
	6.3 – 14.7	27.2	5,843	27.5	5,904	26.7	5,729	22.9	4,915
	> 14.8	46.6	10,003	38.2	8,206	30.4	6,525	21.4	4,584
Race	White	92.7	19,897	91.5	19,632	87.8	18,837	65.8	14,130
	Black	0.5	106	1.8	377	4.6	987	23.7	5,088
	Hispanic	0.9	196	2.0	439	3.2	677	7.3	1,557
	Other Minority	5.9	1,264	4.7	1,014	4.5	961	3.2	688

Income (total yearly)	< \$20,000	9.6	2,051	11.3	2,424	14.8	3,166	21.9	4,700
	\$20,000 - \$34,999	20.5	4,391	22.7	4,872	24.9	5,337	25.0	5,368
	\$35,000 - \$49,999	25.2	5,400	21.7	4,657	19.5	4,192	16.5	3,539
	\$50,000 - \$74,999	12.8	2,740	20.1	4,318	24.1	5,169	26.6	5,718
	\$75,000 +	32.1	6,880	24.2	5,188	16.8	3,596	9.9	2,135
Education	< High school diploma/GED	0.9	191	2.1	440	3.9	848	9.5	2,030
	High school diploma/GED	4.1	873	11.6	2,492	20.5	4,403	28.8	6,181
	School after high school	19.2	4,122	36.6	7,849	45.8	9,835	46.6	10,007
	College degree or higher	75.8	16,277	49.8	10,681	29.7	6,376	15.1	3,245
Cigarette smoking	Current	6.7	1,435	6.0	1,287	5.7	1,228	6.0	1,289
	Past	41.9	8,990	43.1	9,243	42.8	9,194	42.0	9,018
	Never	51.4	11,038	50.9	10,932	51.4	11,040	52.0	11,156
Premature family history of cardiovascular disease	Yes	15.1	3,241	17.2	3,684	18.1	3,872	20.1	4,324
Hypertensive ^c	Yes	29.8	6,386	34.1	7,313	38.6	8,292	48.6	10,421
Treated diabetes	Yes	1.3	288	1.9	404	3.3	710	7.2	1,543
Current statin use	Yes	5.4	1,160	6.6	1,409	7.0	1,509	7.9	1,705
Current daily aspirin use (≥80 mg)	Yes	8.0	1,715	15.9	3,416	22.9	4,913	30.4	6,518
Postmenopausal hormone use	Current user	51.8	11,125	50.6	10,863	48.7	10,450	40.7	8,737
	Never used	35.0	7,502	36.1	7,739	37.4	8,023	45.2	9,702
	Past user	13.2	2,836	13.3	2,860	13.9	2,989	14.1	3,024

Postmenopausal hormone treatment in the WHI hormone trial (DM-C only)	Estrogen placebo	1.8	63	2.3	110	3.2	187	5.2	353
	Active estrogen	1.4	48	2.3	113	3.1	182	5.5	375
	Estrogen plus progestin placebo	3.4	117	4.4	213	4.6	269	5.5	374
	Active estrogen plus progestin	3.7	129	4.4	214	5.0	294	5.5	378
	Not randomized	89.7	3,108	86.6	4,193	84.1	4,937	78.4	5,363

		GM	(2.5, 97.5) Percentile	GM	(2.5, 97.5) Percentile	GM	(2.5, 97.5) Percentile	GM	(2.5, 97.5) Percentile
Calibrated Intake	Sodium/potassium	0.77	(0.48, 1.13)	0.94	(0.63, 1.38)	1.07	(0.71, 1.55)	1.27	(0.82, 1.97)
Distribution ^d	Sodium (mg/d)	2110.0	(957.9, 4170.2)	2400.1	(1088.5, 4787.8)	2567.7	(1137.2, 5271.8)	2753.8	(1136.2, 6186.0)
	Potassium (mg/d)	2738.9	(1375.6, 5096.4)	2549.1	(1226.4, 4787.5)	2409.9	(1109.8, 4677.2)	2165.3	(900.9, 4612.7)

Abbreviations: BMI, body mass index (weight (kg)/height(m)²; GM, geometric mean; METs, metabolic equivalent units;

^aBaseline refers to one year post-randomization in the DM-C and enrollment in the OS.

^bNumber of participants for whom there were no missing values for the nutrients regression calibration or for hypertension or cardiovascular event analysis. Women with missing data on hypertension status or hypertension treatment are excluded.

^cBaseline hypertension was defined as systolic blood pressure >140 or diastolic blood pressure >90, or taking anti-hypertension medication.

^dNumbers shown are the geometric mean, and the sample 2.5 – 97.5 percentile for calibrated intake.

Web Table 2. Calibration Equation^a from Linear Regression of Biomarker Log(sodium/energy) on Self-reported Log(sodium/energy) and Other Characteristics in the Women’s Health Initiative Nutrition and Physical Activity Assessment Study, Enrolled During 2007-2009 (N=340)

	Estimate	SE	R ²	Adjusted R ²
(Intercept)	0.271	0.087 ^b		
Log(sodium/energy) Self-Report ^c	0.384	0.099 ^b	4.2	22.3
Age (years) ^c	0.0002	0.003	0.001	0.01
Body Mass Index (kg/m ²) ^c	-0.001	0.003	0.02	0.1
Race (vs. White)			0.7	3.7
Black	0.033	0.059		
Hispanic	0.024	0.065		
Other Minority	-0.133	0.108		
Dietary Supplementation (0 - no, 1 - yes)	-0.047	0.038	0.2	0.9
Current Smoker (0 - no, 1 - yes)	-0.13	0.115	0.05	0.3
Education (vs. <High school diploma/GED)			2.1	11.1
High school diploma/GED	0.042	0.079		
College degree or more	-0.115	0.043		
Family Income (\$ thousands vs. <20)			0.7	3.7
20 - 34	0.056	0.085		
-35 - 49	0.013	0.091		
50 - 74	0.036	0.094		
>75	0.015	0.089		
Aspirin Use (≥ 80 mg/day) (0 - no, 1 - yes)	0.138	0.050 ^b	1.3	6.9
TOTAL			9.2	48.9

Abbreviations: R², percent of response variable variation explained; SE, standard error

^aCalibration equations were developed based on primary and reliability samples together. R² and adjusted R² were computed using primary, but not reliability sample from the Nutrition and Physical Activity Assessment Study. Adjusted R² values are formed by dividing corresponding

R^2 values by the estimated correlation between the paired biomarker assessments in the Nutrition and Physical Activity Assessment Study reliability subsample (n=90). Sodium and potassium are measured in units of mg/d.

^bSignificance level $p < 0.05$

^cTo interpret intercept, note that $\log(\text{sodium/energy})$ is centered at 0.50; age is centered at 70.9 years; and BMI is centered at 28.2 kg/m^2 .

Web Table 3. Calibration Equation^a from Linear Regression of Biomarker

Log(potassium/energy) on Self-reported Log(potassium/energy) and Other Characteristics in the Women's Health Initiative Nutrition and Physical Activity Assessment Study, Enrolled During 2007-2009 (N=345)

	Estimate	SE	R ²	Adjusted R ²
(Intercept)	0.135	0.075 ^b		
Log(sodium/energy) Self-Report ^c	0.435	0.090 ^b	7.1	16.6
Age (years) ^c	0.003	0.003	1.8	4.3
Body Mass Index (kg/m ²) ^c	-0.013	0.003	6	14.1
Race (vs. White)			5.5	13
Black	-0.232	0.054 ^b		
Hispanic	-0.097	0.046 ^b		
Other Minority	-0.161	0.099		
Dietary Supplementation (0 - no, 1 - yes)	0.006	0.035	0.04	0.1
Current Smoker (0 - no, 1 - yes)	0.017	0.102	0.02	0.05
Education (vs. <High school diploma/GED)			0.4	0.9
High school diploma/GED	-0.018	0.056		
College degree or more	0.044	0.041		
Family Income (\$ thousands vs. <20)			2.1	4.9
20 - 34	0.031	0.072		
35-49	-0.015	0.074		
50 - 74	-0.111	0.074		
>75	-0.043	0.076		
Total			23.0	53.9

Abbreviations: R², percent of response variable variation explained; SE, standard error

^aCalibration equations were developed based on primary and reliability samples together. R² and adjusted R² were computed using primary, but not reliability sample from the Nutrition and Physical Activity Assessment Study. Adjusted R² values are formed by dividing corresponding

R^2 values by the estimated correlation between the paired biomarker assessments in the Nutrition and Physical Activity Assessment Study reliability subsample (n=90). Sodium and potassium are measured in units of mg/d.

^bSignificance level $p < 0.05$

^cTo interpret intercept, note that $\log(\text{potassium/energy})$ is centered at 0.544; age is centered at 70.9 years; and BMI is centered at 28.2 kg/m^2 .

Web Table 4. Calibration Equation^a from Linear Regression of Biomarker Log(energy) on Self-reported Log(energy) and Other Characteristics in the Women’s Health Initiative Nutrition and Physical Activity Assessment Study, Enrolled During 2007-2009 (N=382)

	Estimate	SE	R ²	Adjusted R ²
(Intercept)	7.599	0.029 ^b		
Log(sodium/energy) Self-Report ^c	0.070	0.015 ^b	3.7	6.1
Age (years) ^c	-0.010	0.001 ^b	17.0	28.1
Body Mass Index (kg/m ²) ^c	0.013	0.001 ^b	19.2	31.9
Race (vs. White)			2.0	3.2
Black	-0.030	0.019		
Hispanic	-0.077	0.022 ^b		
Other Minority	-0.047	0.032		
Dietary Supplementation (0 - no, 1 - yes)	0.004	0.013	0.02	0.03
Current Smoker (0 - no, 1 - yes)	-0.033	0.043	0.2	0.4
Education (vs. <High school diploma/GED)			0.01	0.01
High school diploma/GED	0.013	0.025		
College degree or more	0.015	0.015		
Family Income (\$ thousands vs. <20)			1.0	1.6
20 - 34	0.020	0.027		
35 - 49	0.040	0.031		
50 - 74	0.005	0.029		
>75	0.002	0.029		
Aspirin Use (≥80 mg/day) (0 - no, 1 - yes)				
Hypertension	-0.040	0.017 ^b	0.8	1.4
Total			43.9	72.7

Abbreviations: R^2 , percent of response variable variation explained; SE, standard error

^aCalibration equations were developed based on primary and reliability samples together. R^2 and adjusted R^2 were computed using primary, but not reliability sample from the Nutrition and Physical Activity Assessment Study. Adjusted R^2 values are formed by dividing corresponding R^2 values by the estimated correlation between the paired biomarker assessments in the Nutrition and Physical Activity Assessment Study reliability subsample (n=90). Sodium and potassium are measured in units of mg/d.

^bSignificance level $p < 0.05$

^cTo interpret intercept, note that $\log(\text{energy})$ is centered at 7.27 with energy in kcal/day; age is centered at 70.9 years; and BMI is centered at 28.2 kg/m^2 .

Web Table 5. Baseline^a Characteristics for Participants (N=85,850) in the Women’s Health Initiative Dietary Modification Trial Comparison Group and Observational Study, Enrolled During 1994-1998, by Quartile of the Calibrated Sodium Intake

		Quartile of the Calibrated Sodium Intake							
		1 st		2 nd		3 rd		4 th	
		(N=21463)		(N=21462)		(N=21462)		(N=21463)	
		%	N ^b	%	N ^b	%	N ^b	%	N ^b
Age (years)	50-59	16.8	3,605	28.6	6,142	36.9	7,919	47.7	10,239
	60-69	44.2	9,493	46.7	10,023	47.2	10,128	43.6	9,357
	70-79	38.7	8,302	24.6	5,269	15.8	3,397	8.7	1,864
	80-85	0.3	63	0.1	28	0.1	18	0.0	2
BMI (kg/m ²)	Normal (< 25.0)	63.1	13,553	45.1	9,686	30.9	6,632	12.7	2,725
	Overweight (25.0 - 29.9)	30.0	6,448	38.9	8,344	40.5	8,686	29.4	6,310
	Obese (≥ 30)	6.8	1,462	16.0	3,432	28.6	6,144	57.9	12,428
Recreational physical activity (MET – hours/week)	< 1.5	14.8	3,183	15.6	3,351	18.2	3,896	25.5	5,469
	1.5 - 6.2	19.0	4,087	20.8	4,459	21.4	4,596	23.8	5,100
	6.3 – 14.7	26.5	5,683	26.9	5,763	26.7	5,739	24.3	5,206
	> 14.8	39.6	8,510	36.8	7,889	33.7	7,231	26.5	5,688
Race	White	77.0	16,521	86.6	18,579	88.1	18,902	86.2	18,494
	Black	6.0	1,286	6.9	1,491	7.6	1,626	10.0	2,155
	Hispanic	3.4	720	3.5	741	3.3	699	3.3	709
	Other Minority	13.7	2,936	3.0	651	1.1	235	0.5	105
Income (total yearly)	< \$20,000	17.4	3,744	14.6	3,126	13.2	2,829	12.3	2,642
	\$20,000 - \$34,999	16.2	3,472	20.5	4,396	24.6	5,273	31.8	6,827

	\$35,000 - \$49,999	18.8	4,030	20.0	4,284	21.2	4,549	22.9	4,925
	\$50,000 - \$74,999	21.2	4,550	21.5	4,612	21.3	4,576	19.6	4,207
	\$75,000 +	26.4	5,666	23.5	5,042	19.7	4,230	13.3	2,861
Education	< High school diploma/GED	2.4	524	3.1	675	4.6	983	6.2	1,327
	High school diploma/GED	6.8	1,454	11.7	2,509	17.6	3,767	29.0	6,219
	School after high school	25.4	5,441	34.4	7,392	42.0	9,011	46.4	9,969
	College degree or higher	65.4	14,044	50.7	10,886	35.9	7,701	18.4	3,948
Cigarette smoking	Current	14.0	3,008	5.7	1,226	3.2	677	1.5	328
	Past	36.9	7,912	42.0	9,013	44.3	9,501	46.7	10,019
	Never	49.1	10,543	52.3	11,223	52.6	11,284	51.8	11,116
Premature family history of cardiovascular disease	Yes	14.8	3,171	16.9	3,633	18.0	3,858	20.8	4,459
Hypertensive ^c	Yes	39.8	8,533	36.1	7,744	35.8	7,677	39.4	8,458
Treated diabetes	Yes	2.0	431	2.4	509	3.2	695	6.1	1,310
Current statin use	Yes	5.9	1,261	6.5	1,393	7.0	1,507	7.6	1,622
Current daily aspirin use (≥80 mg)	Yes	6.5	1,405	13.5	2,892	21.5	4,620	35.6	7,645
Postmenopausal hormone use	Current user	47.4	10,164	48.8	10,484	49.4	10,607	46.2	9,920
	Never used	38.5	8,264	37.5	8,045	37.2	7,991	40.4	8,666
	Past user	14.1	3,035	13.7	2,933	13.3	2,864	13.4	2,877
Postmenopausal hormone treatment	Estrogen placebo	2.3	104	3.1	158	3.1	169	4.6	282
	Active estrogen	2.2	99	2.4	119	3.7	202	4.9	298

in the WHI hormone trial (DM-C only)	Estrogen plus progestin placebo	3.9	173	4.3	218	4.6	254	5.4	328
	Active estrogen plus progestin	4.4	194	4.3	215	4.8	261	5.7	345
	Not randomized	87.1	3,862	85.9	4,333	83.8	4,592	79.3	4,814

		GM	(2.5, 97.5) Percentile	GM	(2.5, 97.5) Percentile	GM	(2.5, 97.5) Percentile	GM	(2.5, 97.5) Percentile
Calibrated	Sodium/potassium Intake	0.87	(0.49, 1.52)	0.96	(0.58, 1.60)	1.03	(0.62, 1.67)	1.14	(0.69, 1.86)
	Sodium (mg/d)	2007.2	(903.3, 4159.6)	2345.3	(1091.8, 4701.7)	2569.2	(1201.6, 5103.4)	2960.7	(1356.1, 6244.9)
Distribution ^d	Potassium (mg/d)	2298.8	(1009.4, 4514.5)	2434.7	(1107.4, 4677.5)	2506.4	(1127.4, 4806.1)	2597.1	(1151.0, 5114.8)

Abbreviations: BMI, body mass index (weight (kg)/height(m)²; GM, geometric mean; METs, metabolic equivalent units;

^aBaseline refers to one year post-randomization in the DM-C and enrollment in the OS.

^bNumber of participants for whom there were no missing values for the nutrients regression calibration or for hypertension or cardiovascular event analysis. Women with missing data on hypertension status or hypertension treatment are excluded.

^cBaseline hypertension was defined as systolic blood pressure >140 or diastolic blood pressure >90, or taking anti-hypertension medication.

^dNumbers shown are the geometric mean, and the sample 2.5 – 97.5 percentile for calibrated intake.

Web Table 6. Baseline^a Characteristics for Participants (N=85,850) in the Women’s Health Initiative Dietary Modification Trial Comparison Group and Observational Study, Enrolled During 1994-1998, by Quartile of the Calibrated Potassium Intake

		Quartile of the Calibrated Potassium Intake							
		1 st		2 nd		3 rd		4 th	
		(N=21463)		(N=21462)		(N=21462)		(N=21463)	
		%	N ^b	%	N ^b	%	N ^b	%	N ^b
Age (years)	50-59	28.4	6,094	25.6	5,500	32.0	6,871	44.0	9,440
	60-69	44.4	9,519	46.9	10,068	47.2	10,127	43.3	9,287
	70-79	27.0	5,800	27.3	5,856	20.7	4,447	12.7	2,729
	80-85	0.2	50	0.2	37	0.1	17	0.0	7
BMI (kg/m ²)	Normal (< 25.0)	29.9	6,416	36.1	7,756	39.9	8,561	46.0	9,863
	Overweight (25.0 - 29.9)	34.6	7,431	35.3	7,572	35.3	7,580	33.6	7,205
	Obese (≥ 30)	35.5	7,616	28.6	6,134	24.8	5,321	20.5	4,395
Recreational physical activity (MET – hours/week)	< 1.5	27.5	5,906	20.4	4,383	15.3	3,294	10.8	2,316
	1.5 - 6.2	24.8	5,316	22.9	4,914	20.4	4,373	17.0	3,639
	6.3 – 14.7	23.8	5,113	25.7	5,512	27.7	5,955	27.1	5,811
	> 14.8	23.9	5,128	31.0	6,653	36.5	7,840	45.2	9,697
Race	White	47.1	10,116	92.7	19,898	98.3	21,096	99.6	21,386
	Black	28.3	6,067	1.8	390	0.4	84	0.1	17
	Hispanic	9.6	2,070	2.7	590	0.8	170	0.2	39
	Other Minority	15.0	3,210	2.7	584	0.5	112	0.1	21
Income (total yearly)	< \$20,000	24.1	5,169	15.5	3,324	10.7	2,299	7.2	1,549
	\$20,000 - \$34,999	17.2	3,688	20.6	4,414	24.6	5,289	30.6	6,577

	\$35,000 - \$49,999	13.9	2,987	17.9	3,845	22.7	4,869	28.4	6,087
	\$50,000 - \$74,999	31.3	6,721	27.3	5,868	17.5	3,765	7.4	1,591
	\$75,000 +	13.5	2,897	18.7	4,009	24.4	5,237	26.4	5,656
Education	< High school diploma/GED	8.8	1,883	4.0	858	2.3	492	1.2	276
	High school diploma/GED	20.9	4,476	19.6	4,199	15.0	3,217	9.6	2,057
	School after high school	43.1	9,260	42.5	9,117	36.0	7,737	26.6	5,699
	College degree or higher	27.2	5,844	34.0	7,288	46.7	10,016	62.6	13,431
Cigarette smoking	Current	9.1	1,944	6.4	1,381	5.1	1,094	3.8	820
	Past	37.4	8,030	42.6	9,139	44.0	9,454	45.8	9,822
	Never	53.5	11,489	51.0	10,942	50.9	10,914	50.4	10,821
Premature family history of cardiovascular disease	Yes	17.3	3,704	18.4	3,943	17.7	3,807	17.1	3,667
Hypertensive ^c	Yes	51.5	11,049	41.3	8,871	33.7	7,237	24.5	5,255
Treated diabetes	Yes	6.0	1,288	3.2	679	2.5	542	2.0	436
Current statin use	Yes	7.6	1,621	7.0	1,497	6.7	1,434	5.7	1,231
Current daily aspirin use (≥80 mg)	Yes	16.1	3,465	20.7	4,440	20.7	4,437	19.7	4,220
Postmenopausal hormone use	Current user	40.7	8,741	47.8	10,261	50.3	10,789	53.0	11,384
	Never used	45.0	9,664	37.8	8,107	36.2	7,777	34.6	7,418
	Past user	14.2	3,058	14.4	3,094	13.5	2,896	12.4	2,661
Postmenopausal hormone treatment	Estrogen placebo	4.3	282	3.4	204	2.7	139	2.6	88
	Active estrogen	4.8	313	3.2	190	2.5	130	2.5	85

in the WHI hormone trial (DM-C only)	Estrogen plus progestin placebo	4.7	303	5.1	306	4.0	203	4.8	161
	Active estrogen plus progestin	4.9	320	4.8	289	5.1	262	4.3	144
	Not randomized	81.2	5,276	83.6	5,040	85.6	4,377	85.9	2,908

		GM	(2.5, 97.5) Percentile	GM	(2.5, 97.5) Percentile	GM	(2.5, 97.5) Percentile	GM	(2.5, 97.5) Percentile
Calibrated	Sodium/potassium	1.2	(0.68, 1.97)	1.06	(0.64, 1.62)	0.95	(0.60, 1.44)	0.82	(0.49, 1.25)
Intake Distribution ^d	Sodium (mg/d)	2319.2	(951.4, 5562.3)	2489.4	(1094.5, 5326.6)	2501.7	(1120.1, 5141.1)	2479.3	(1133.2, 5004.8)
	Potassium (mg/d)	1938.7	(858.5, 4099.3)	2354.0	(1187.4, 4420.6)	2626.0	(1379.8, 4706.3)	3040.0	(1638.4, 5405.0)

Abbreviations: BMI, body mass index (weight (kg)/height(m)²; GM, geometric mean; METs, metabolic equivalent units;

^aBaseline refers to one year post-randomization in the DM-C and enrollment in the OS.

^bNumber of participants for whom there were no missing values for the nutrients regression calibration or for hypertension or cardiovascular event analysis. Women with missing data on hypertension status or hypertension treatment are excluded.

^cBaseline hypertension was defined as systolic blood pressure >140 or diastolic blood pressure >90, or taking anti-hypertension medication.

^dNumbers shown are the geometric mean, and the sample 2.5 – 97.5 percentile for calibrated intake.

Web Table 7. Hazard ratios (HRs) and 95% Confidence Intervals (CIs) for Simultaneous 20% Increments in Uncalibrated Food Frequency Questionnaire (FFQ) Sodium and Potassium Intake, in Combined Analyses of Data from the Women’s Health Initiative Dietary Modification Trial Comparison Group (DM-C) and Observational Study (OS) from Baseline^a (1994-1998) to September 30, 2010 (N=93,602)

Cardiovascular Disease Outcome	Uncalibrated Sodium/Potassium		Uncalibrated Sodium		Uncalibrated Potassium	
	HR	95% CI	HR	95% CI	HR	95% CI
	CHD	1.05	1.03, 1.07	1.05	1.02, 1.07	0.94
Non-fatal MI	1.06	1.03, 1.08	1.05	1.02, 1.08	0.94	0.92, 0.97
Coronary death	1.05	1.01, 1.09	1.05	1.01, 1.09	0.93	0.89, 0.97
CABG and PCI	1.06	1.04, 1.09	1.06	1.04, 1.08	0.93	0.91, 0.95
Stroke	1.01	0.99, 1.04	1.01	0.98, 1.03	0.98	0.95, 1.00
Ischemic stroke	1.03	1.00, 1.06	1.03	1.00, 1.06	0.96	0.93, 0.99
Hemorrhagic stroke	0.93	0.88, 0.98	0.92	0.87, 0.98	1.06	0.99, 1.13
Total CVD	1.03	1.02, 1.05	1.03	1.01, 1.05	0.96	0.94, 0.98
Total CVD with CABG and PCI	1.04	1.02, 1.05	1.03	1.02, 1.05	0.95	0.94, 0.97
Heart Failure	1.04	1.01, 1.07	1.05	1.01, 1.08	0.97	0.94, 1.01

Abbreviations: CABG, coronary artery bypass graft; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; DM-C, dietary modification trial comparison

group; HR, hazard ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention;
OS, observational study

^aBaseline defined as 1 year from randomization in the Dietary Modification Trial Comparison
Group and enrollment in the Observational Study

Web Table 8. Cardiovascular disease hazard ratios (HRs) and 95% Confidence Intervals (CIs) for a 20% Increment in the Ratio of Sodium to Potassium Intake in the Women's Health Initiative Dietary Modification Trial Comparison Group (DM-C)

and Observational Study (OS) Separately, With and Without Biomarker Calibration of the Food Frequency Questionnaire (FFQ)-based Dietary Data, from Baseline^a (1994-1998) to September 30, 2010

Cardiovascular Disease Outcome	DM-C				OS			
	Uncalibrated		Calibrated		Uncalibrated		Calibrated	
	(N=22678)		(N=21267)		(N=70924)		(N=65177)	
	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI
CHD	1.05	1.00, 1.09	1.15	1.03, 1.28	1.05	1.02, 1.08	1.12	1.03, 1.22
Non-fatal MI	1.05	0.99, 1.11	1.11	0.99, 1.24	1.06	1.03, 1.09	1.13	1.04, 1.23
Coronary death	1.06	0.97, 1.15	1.27	1.05, 1.53	1.05	1.01, 1.10	1.13	1.00, 1.27
CABG and PCI	1.05	1.01, 1.10	1.14	1.02, 1.26	1.07	1.04, 1.09	1.16	1.07, 1.26
Stroke	1.03	0.98, 1.09	1.08	0.96, 1.21	1.01	0.98, 1.04	1.05	0.98, 1.12
Ischemic stroke	1.04	0.98, 1.11	1.12	0.97, 1.29	1.03	1.00, 1.06	1.08	1.01, 1.17
Hemorrhagic stroke	0.97	0.86, 1.09	0.89	0.71, 1.12	0.92	0.86, 0.98	0.87	0.77, 0.99
Total CVD	1.04	1.01, 1.08	1.12	1.02, 1.24	1.03	1.01, 1.05	1.09	1.02, 1.17
Total CVD with CABG and PCI	1.05	1.02, 1.08	1.12	1.03, 1.23	1.04	1.02, 1.05	1.10	1.03, 1.18
Heart Failure	1.03	0.97, 1.11	1.19	0.98, 1.45	1.04	1.00, 1.08	1.21	1.01, 1.43

Abbreviations: CABG, coronary artery bypass graft; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; DM-C, dietary modification trial comparison group; HR, hazard ratio; MI = myocardial infarction; PCI = percutaneous coronary intervention; OS, observational study

^aBaseline defined as 1 year following enrollment in the Dietary Modification Trial Comparison Group, and enrollment in the Observational study